Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Cotton

Showing results (341-350 of 474) with videos related to

Pageof 48
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2018
Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed ChildrenEleonora A M L Mutsaerts, Marta C Nunes, Martijn N van Rijswijk, et al.
Vaccine|December 12, 2012
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infantsShabir A Madhi, Alane Izu, Avye Violari, et al.
Neuroimage. Clinical|January 5, 2021
MRS suggests multi-regional inflammation and white matter axonal damage at 11 years following perinatal HIV infectionAmy S Graham, Martha J Holmes, Francesca Little, et al.
Journal of the International AIDS Society|July 14, 2021
Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigationKaylee S van Wyhe, Barbara Laughton, Mark F Cotton, et al.
Plos One|July 13, 2017
Longitudinal increases of brain metabolite levels in 5-10 year old childrenMartha J Holmes, Frances C Robertson, Francesca Little, et al.
The Pediatric Infectious Disease Journal|December 6, 2017
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 StudyMark F Cotton, Afaaf Liberty, Indiana Torres-Escobar, et al.
The Journal of Infectious Diseases|June 30, 2010
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infantsShabir A Madhi, Peter Adrian, Mark F Cotton, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 10, 2016
Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention studyE R Maritz, G Montepiedra, L Liu, et al.
Metabolic Brain Disease|December 7, 2017
Altered brain morphometry in 7-year old HIV-infected children on early ARTEmmanuel C Nwosu, Frances C Robertson, Martha J Holmes, et al.
AIDS Research and Human Retroviruses|July 8, 2024
Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral TherapyLisa L Ross, Mark F Cotton, Haseena Cassim, et al.
Pageof 48

Showing results (341-350 of 474) with videos related to

Sort By:
Pageof 48
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2018
Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed ChildrenEleonora A M L Mutsaerts, Marta C Nunes, Martijn N van Rijswijk, et al.
Vaccine|December 12, 2012
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infantsShabir A Madhi, Alane Izu, Avye Violari, et al.
Neuroimage. Clinical|January 5, 2021
MRS suggests multi-regional inflammation and white matter axonal damage at 11 years following perinatal HIV infectionAmy S Graham, Martha J Holmes, Francesca Little, et al.
Journal of the International AIDS Society|July 14, 2021
Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigationKaylee S van Wyhe, Barbara Laughton, Mark F Cotton, et al.
Plos One|July 13, 2017
Longitudinal increases of brain metabolite levels in 5-10 year old childrenMartha J Holmes, Frances C Robertson, Francesca Little, et al.
The Pediatric Infectious Disease Journal|December 6, 2017
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 StudyMark F Cotton, Afaaf Liberty, Indiana Torres-Escobar, et al.
The Journal of Infectious Diseases|June 30, 2010
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infantsShabir A Madhi, Peter Adrian, Mark F Cotton, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 10, 2016
Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention studyE R Maritz, G Montepiedra, L Liu, et al.
Metabolic Brain Disease|December 7, 2017
Altered brain morphometry in 7-year old HIV-infected children on early ARTEmmanuel C Nwosu, Frances C Robertson, Martha J Holmes, et al.
AIDS Research and Human Retroviruses|July 8, 2024
Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral TherapyLisa L Ross, Mark F Cotton, Haseena Cassim, et al.
Pageof 48